[ad_1]
Dublin, January 17, 2022 /PRNewswire/—— “Nonsomnia Drugs Market – Global Industry Analysis (2018 – 2020) – Growth Trends and Market Forecast (2021 – 2026)” report added to ResearchAndMarkets.com’s supply.
The report indicates that the global narcolepsy drugs market valuation will reach $6.588 billion By 2025 from $3,875.1 million 2021.
Demand for these drugs will be driven up by improved diagnosis of the condition, which makes excessive daytime sleepiness. Although a relatively rare disease, analysts predict that demand for the disease will be driven by greater awareness of the medical condition. Its symptoms, such as cataplexy and hallucinations, can be life-threatening, prompting players to invest in drug development. The global narcolepsy drugs market is expected to surge at a CAGR of 11.2% between the forecast years of 2021 to 2025, indicating steady growth.
Conclusive diagnosis of narcolepsy manifested by cataplexy leads the global narcolepsy drug market
The COVID-19 pandemic has brought about a range of sleep disorders, underscoring the need to treat them to improve daytime wakefulness and productivity. Narcolepsy with cataplexy or type 1 narcolepsy is expected to account for 68.8% of the market in 2021. The segment is expected to lead the global narcolepsy drug market as the combination of the two ensures a conclusive diagnosis. The report noted that despite treatment for narcolepsy, patients may experience cataplexy later in life. According to the National Sleep Foundation, more than 60 percent of people with narcolepsy have type 1 narcolepsy. Hence, this segment is expected to dominate the global market during the forecast period.
Sodium oxylate will dominate as it remains critical in the management of EDS and cataplexy
The demand for stimulants and selective serotonin for the control of narcolepsy will dominate the global narcolepsy drugs market. Sodium oxybate, selective serotonin, is expected to…
The full story is available on Benzinga.com
[ad_2]
Source link
